^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Matulane (procarbazine hydrochloride)

    Company:
    Leadiant Biosci
    Drug class:
    Alkylating agent
    Related drugs:
    24d
    Concurrent cytomegalovirus iridocyclitis and vitreoretinal lymphoma in the same eye during long-term infliximab therapy: a case report. (PubMed, J Ophthalmic Inflamm Infect)
    The present case highlights both the risk of opportunistic ocular infections and lymphoproliferative disorders associated with prolonged immunosuppression and the diagnostic challenge when both conditions coexist in the same eye. Careful monitoring and close collaboration between ophthalmologists and internists are essential for the early diagnosis and appropriate management of such patients.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus) • IL6R (Interleukin 6 receptor)
    |
    Rituxan (rituximab) • methotrexate • vincristine • Matulane (procarbazine hydrochloride)
    2ms
    Comparative Outcomes of Consolidation Strategies After R-MVP Induction in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. (PubMed, Cancer Med)
    ASCT was associated with the most durable survival among consolidation strategies after R-MVP induction. These findings, derived from a large real-world, multi-institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.
    Clinical • Retrospective data • Journal
    |
    MVP (Major Vault Protein)
    |
    LDH elevation
    |
    Rituxan (rituximab) • methotrexate • vincristine • Matulane (procarbazine hydrochloride) • methotrexate IV
    3ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Trial initiation date
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    4ms
    CA082-1215: Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma (2025-521144-38-00)
    P1/2, N=31, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P1/2 trial
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride) • Actemra IV (tocilizumab)
    4ms
    ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov)
    P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033
    Trial completion date • Trial primary completion date • HEOR
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
    4ms
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)
    5ms
    Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (clinicaltrials.gov)
    P3, N=305, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Oct 2025 --> Oct 2029 | Trial primary completion date: Oct 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    temozolomide • vincristine • Matulane (procarbazine hydrochloride)
    7ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    9ms
    LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (clinicaltrials.gov)
    P1/2, N=118, Active, not recruiting, Institut Curie | Trial primary completion date: Aug 2025 --> Feb 2035
    Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Matulane (procarbazine hydrochloride)
    12ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P2 trial
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    1year
    Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • vincristine • Matulane (procarbazine hydrochloride) • Velexbru (tirabrutinib)
    1year
    Long-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report. (PubMed, Brain Tumor Res Treat)
    After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years...Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated...Continued regression led to complete remission-confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient's peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.
    Journal
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)